Oxygen Therapy Remote Monitoring in COPD Patients.

Observational Study: Oxygen Therapy Monitoring in COPD Patients Using Connected Devices.

Background : Long-term oxygen therapy is prescribed for patients with severe COPD. The aim of oxygen therapy is to administer oxygen at a concentration level higher than that of ambient air, in order to treat or prevent the symptoms and manifestations of arterial hypoxemia; this therapy can be applied either in an acute situation or as a long-term treatment, in cases of stabilized severe chronic hypoxemia.

Currently, pneumologists do not have the possibility, between 2 consultations spaced several months apart, to measure the patient's compliance with the treatment (adherence to oxygen therapy) nor the respect of the prescribed dosage (O2 flow and duration). In addition to the patient's adherence to the treatment, the specialist does not have the possibility to assess the patient's physical activity (walking ...).

This observational study is a e-health, prospective, multicenter study conducted in France under the control of pneumologists.

The main objective of this study is to evaluate the adherence to oxygen therapy in real life, and its evolution, in COPD patients justifying a long term oxygen therapy in stable state.

Study Overview

• Status: Completed
• Conditions: Chronic Obstructive Pulmonary Disease

Detailed Description

The observational study consists in collecting physiological data (cardiorespiratory and physical activity) and use of the oxygen therapy device in real life during the first months after the initiation of treatment.

For this purpose, two connected medical devices will be provided to each patient during 2 periods of 2 weeks (weeks 6 to 8 then weeks 12 to 14 after the initiation of oxygen therapy). The devices are: 1/ a connected watch that continuously measures vital parameters (heart rate and blood oxygen saturation), and physical activity parameters (no. of steps, distance, duration of effort), and 2/ a Teleox device that remotely monitors patients equipped with an oxygen source (it measures the oxygen flow rate requested by the patient, the duration of use of the oxygen source, and the breathing rate).

Study design: a cohort of 250 patients with COPD newly initiated a long term oxygen therapy will be enrolled in the study and follow-up over 6 months. Data will be collected by lung specialists and home health care provider teams at 2 months, 3.5 months and 6 months post-initiation of oxygen therapy.

• Study Type: Observational
• Enrollment (Actual): 159

Contacts and Locations

Study Locations

• France
  • Aix-en-Provence, France
    • CHIAP
  • Annonay, France, 07103
    • CH Nord Ardèche
  • Antibes, France
    • Cabinet privé
  • Aubagne, France, 13400
    • Hopital Privé de La Casamance
  • Avignon, France
    • Ch Avignon
  • Avignon, France
    • Cabinet libéral
  • Blois, France
    • CH Blois
  • Briis-sous-Forges, France
    • CH Bligny
  • Cannes, France
    • CH Cannes
  • Clamart, France, 92140
    • Hôpital Percy
  • Clermont-Ferrand, France, 63000
    • Chu Gabriel Montpied
  • Draguignan, France, 83007
    • CH Draguignan
  • Foix, France
    • Cabinet libéral
  • Le Puy-en-Velay, France, 43000
    • CH Emile Roux
  • Le Puy-en-Velay, France
    • Cabinet libéral
  • Libourne, France
    • CH Libourne
  • Lille, France, 59800
    • Hôpital La Louvière
  • Lyon, France
    • Centre médical Parot
  • Marseille, France, 13285
    • Hopital Saint Joseph
  • Marseille, France
    • AP-HM Hopital Nord
  • Marseille, France, 13384
    • Hôpital d'Instruction des Armées Laveran
  • Martigues, France, 13698
    • CH de Martigues
  • Melun, France, 77000
    • GHSIF / CH Melun
  • Montfermeil, France
    • GHI Le Raincy
  • Nancy, France, 54511
    • CHRU Nancy-Université de Lorraine
  • Ollioules, France
    • Polyclinique des fleurs
  • Orange, France, 84100
    • CH Louis Giorgi d'Orange
  • Perpignan, France, 66000
    • CH de Perpignan
  • Perpignan, France, 66000
    • Pneumology practice
  • Pessac, France, 33600
    • CHU de Bordeaux
  • Poissy, France
    • Cabinet libéral
  • Saint-Nazaire, France, 44600
    • CH St Nazaire
  • Sainte-Feyre, France
    • MGEN
  • Sallanches, France, 74600
    • cabinet du dr Radu Horia Bumbea
  • Toulon, France
    • Cabinet de Pneumologie
  • Toulouse, France, 31000
    • Clinique Pasteur

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Cohort of COPD patients who initiate long-term oxygen therapy.

Description

Inclusion Criteria:

• COPD patients who require the initiation of a long term oxygen therapy.
• Patient agreeing to use a connected watch and a TeleOx for the remote monitoring of their parameters and physical activity.
• Non-smoker, ex-smoker, or patient agreeing to stop smoking.
• Life expectancy greater than 6 months.
• Signed informed consent form,
• Subject affiliated to a health insurance system, or is a beneficiary.

Exclusion Criteria:

• Patient initiated on oxygen therapy prior to the inclusion visit.
• Patient with cognitive impairment.
• Simultaneous participation in a health intervention research,
• Vulnerable subjects.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of compliance of long term oxygen therapy	For each patient, the average daily duration of oxygen use (expressed as numbers of hours of oxygen use per day) will be measured on period of 14 consecutive days at different times after the initiation of oxygen therapy (weeks 6 to 8, and then weeks 12 to 14). The duration of oxygen use is measured using the TeleOx medical device placed in each oxygen source (fixed and portable sources).	3.5 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Impact of long term oxygen therapy on heart rate	For each patient, the average and maximum daily heart rate (expressed as beats/minute) will be measured on period of 14 consecutive days at different times after the initiation of oxygen therapy (weeks 6 to 8, and then weeks 12 to 14). The heart rate is measured by the connected watch all along the day.	Month 2, Month 3.5
Impact of long term oxygen therapy on oxygen saturation in the blood (SpO2)	For each patient, the average nightime and daytime SpO2 (expressed in %) will be calculated by period of 14 consecutive days at different times after the initiation of oxygen therapy (weeks 6 to 8, and then weeks 12 to 14). The SpO2 is measured by the connected watch (automatically at night and manually in day).	Month 2, Month 3.5
Impact of long term oxygen therapy on the respiratory rate	For each patient, the median, maximum, and 95th percentile daily respiratory rate (expressed in cycles/minute) will be measured on period of 14 consecutive days at different times after the initiation of oxygen therapy (weeks 6 to 8, and then weeks 12 to 14). The respiratory rate is measured using the TeleOx medical device placed in each oxygen source (fixed and portable sources).	Month 2, Month 3.5
Impact of long term oxygen therapy on the physical activity in terms of duration of effort	For each patient, the total duration of effort per day (expressed in hours) will be measured on period of 14 consecutive days at different times after the initiation of oxygen therapy (weeks 6 to 8, and then weeks 12 to 14). The total duration of effort is measured by the connected watch.	Month 2, Month 3.5
Impact of long term oxygen therapy on the physical activity in terms of duration of number of steps	For each patient, the total number of steps per day will be measured on period of 14 consecutive days at different times after the initiation of oxygen therapy (weeks 6 to 8, and then weeks 12 to 14). The number of steps is measured by the connected watch.	Month 2, Month 3.5
Impact of long term oxygen therapy on the health related quality of life of COPD patients	The quality of life will be assessed using the COPD-specific health related quality of life questionnaire named VQ11. The questionnaire VQ11 comprises 11 items distributed across three components (functional: 3 items, psychological: 4 items, social: 4 items). The global score ranges from 11 to 55 points; higher scores mean a better quality of life.	At oxygen therapy initiation (baseline), Month 2, Month 3.5
Impact of long term oxygen therapy on the respiratory function	The pulmonologist will assess the evolution of respiratory function according to good medical practice with the pulmonary functional tests. Based on the VEMS/CV value (expressed in %), the pulmonologist judges if the prescribed long term oxygen therapy is sufficient to normalize the respiratory function or if the treatment must be modified.	At inclusion, Month 6
Assessment of exacerbation	The pulmonologist will assess the number of exacerbation that occured during the first 6-months of long term oxygen therapy.	Month 6

Collaborators and Investigators

• Sponsor: Vivisol
• Collaborators: Slb Pharma
• Investigators: Principal Investigator: Ari CHAOUAT, Pr, CHRU Nancy-Université de Lorraine

Study record dates

Study Major Dates

• Study Start (Actual): January 27, 2023
• Primary Completion (Actual): December 15, 2025
• Study Completion (Actual): February 4, 2026

Study Registration Dates

• First Submitted: July 18, 2022
• First Submitted That Met QC Criteria: July 21, 2022
• First Posted (Actual): July 26, 2022

Study Record Updates

• Last Update Posted (Actual): March 31, 2026
• Last Update Submitted That Met QC Criteria: March 25, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: quality of life; compliance; exacerbation; long term oxygen therapy
• Additional Relevant MeSH Terms: Pathologic Processes; Chronic Disease; Disease Attributes; Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pathological Conditions, Signs and Symptoms; Behavior; Treatment Adherence and Compliance; Health Behavior; Patient Acceptance of Health Care; Pulmonary Disease, Chronic Obstructive; Patient Compliance
• Other Study ID Numbers: O2 Connect; IDRCB 2022-A00825-38 (Other Identifier: French National Health Agency)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No